Overview
- The Phase III results, presented and published on May 31, showed median overall survival of about 13.2 months for patients taking daraxonrasib versus about 6.7 months for those on standard chemotherapy.
- The randomized trial enrolled roughly 500 previously treated patients with metastatic pancreatic cancer and compared daily daraxonrasib pills with standard intravenous chemotherapy.
- Daraxonrasib works by pairing with cyclophilin A to act as a molecular glue that binds and inhibits mutant KRAS, and it is taken as three pills once daily on an empty stomach.
- Side effects commonly include a blistering rash (any rash in about 90% of patients and severe rash in ~14%), diarrhea, nausea and mouth sores, yet only about 1% stopped the drug for toxicity compared with 11% on chemotherapy.
- Regulators have allowed expanded access and Revolution Medicines is preparing expedited filings, clinicians are prioritizing eligible patients and researchers say the drug could be tested earlier in disease or against other KRAS-driven cancers though resistance and biomarker questions remain.